1 / 6

Authors: Dr. R. James et al Date posted: ASCO Oral Presentation June 2009

A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus (ACT II). Authors: Dr. R. James et al Date posted: ASCO Oral Presentation June 2009 Reviewed by: Dr. Christopher Booth.

gaia
Télécharger la présentation

Authors: Dr. R. James et al Date posted: ASCO Oral Presentation June 2009

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A randomised trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5-FU in squamous cell carcinoma of the anus (ACT II) Authors: Dr. R. James et al Date posted: ASCO Oral Presentation June 2009 Reviewed by: Dr. Christopher Booth

  2. 2x2 factorial design to evaluate: • Whether CRT using cisplatin or mitomycin produces a higher complete response rate (1° EP= path CR rate) • Whether maintenance therapy will improve local control or overall survival (1° EP=RFS) CRT Comparison All pts received: 50.4 Gy in 28 fractions 5-FU CIV 1000 mg/m2 D1-4 and 29-32 Pts randomized to receive: 1. Mitomycin 12 mg/m2 D1 only OR 2. Cisplatin 60 mg/m2 D1 and 29 R T1-4 SCC anus No mets Adequate CrCl N=940 Maintenance Therapy Comparison 1. No maintenance therapy after CRT 2. 4 weeks after CRT pts received… 5-FU CIV 1000 mg/m2 D1-4 and 29-32 with Cisplatin 60 mg/m2 D1 and 29

  3. RESULTS

  4. RESULTS

  5. STUDY COMMENTARY • This trial sought to improve on outcomes in anal cancer by exploring whether Cisplatin should be substituted for Mitomycin and whether an additional cycle of maintenance chemotherapy should be given after CRT • This large and well designed RCT did not find benefit to either of these interventions • Cisplatin did not improve complete response rate or colostomy rate • Maintenance therapy did not improve RFS or OS although follow-up is still relatively early • There were no significant differences in the pattern of recurrence (i.e. local, regional, distant) among any of the 4 comparative strategies.

  6. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • This is the 2nd large RCT to evaluate whether cisplatin should replace Mitomycin in anal cancer • The Intergroup RTOG-11 (JAMA 2008) did not find any improvement in outcome with the use of cisplatin in anal cancer • These 2 RCTs suggest that the standard of care for patients with anal cancer continues to be chemoradiotherapy with 5-FU and Mitomycin

More Related